Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $11.00 price target on the biotechnology company’s stock. Chardan Capital‘s target price would indicate a potential upside of 420.09% from the stock’s previous close.
A number of other brokerages also recently issued reports on RCKT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Jefferies Financial Group reissued a “hold” rating and set a $2.95 price objective on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Needham & Company LLC raised shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Wednesday, September 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, November 4th. Finally, Leerink Partners lowered their price target on Rocket Pharmaceuticals from $7.00 to $4.00 and set a “market perform” rating on the stock in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.77.
Read Our Latest Analysis on Rocket Pharmaceuticals
Rocket Pharmaceuticals Stock Down 2.1%
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.03). On average, research analysts anticipate that Rocket Pharmaceuticals will post -1.36 earnings per share for the current year.
Insider Buying and Selling
In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 75,364 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $3.40, for a total value of $256,237.60. Following the transaction, the general counsel directly owned 598,489 shares in the company, valued at approximately $2,034,862.60. This trade represents a 11.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 21.30% of the company’s stock.
Institutional Trading of Rocket Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Rocket Pharmaceuticals in the second quarter worth about $33,940,000. Maverick Capital Ltd. raised its stake in Rocket Pharmaceuticals by 42.0% during the 1st quarter. Maverick Capital Ltd. now owns 3,567,372 shares of the biotechnology company’s stock worth $12,771,000 after acquiring an additional 1,054,262 shares during the period. Monaco Asset Management SAM bought a new position in Rocket Pharmaceuticals in the 2nd quarter worth $8,483,000. Opaleye Management Inc. raised its holdings in Rocket Pharmaceuticals by 4.7% during the second quarter. Opaleye Management Inc. now owns 1,000,000 shares of the biotechnology company’s stock valued at $3,420,000 after acquiring an additional 45,000 shares during the period. Finally, Bank of America Corp DE purchased a new position in Rocket Pharmaceuticals in the 2nd quarter worth approximately $2,512,000. Institutional investors own 98.39% of the company’s stock.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells. The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy.
Featured Articles
- Five stocks we like better than Rocket Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
